Yang Feng

Yang Feng, PhD, is a postdoc scholar at Stanford University. She conducted research at Georgetown University and completed her doctoral training in Guryanova lab at the University of Florida (UF). Her PhD thesis work depicted the causal relationship of DNMT3A-mutant blood cells on aggressive solid tumors for the first time. She studies the preventive therapy for high-risk TP53-mutant AML with primary human samples during postdoc training in Majeti Lab. She has a track of record of publications on high-impact journals including Cancer Discovery. Her exemplary work merited the UF Outstanding Achievement Award and Predoctoral Award in 2020, ASH Abstract Achievement Award in 2021, Stanford PRISM Award in 2022 and the “Best of Year” Award of JEM in 2023, Stanford TRAM Pilot Grant for 2023-2025 and ASH Abstract Achievement Award in 2025. Her career goal is becoming an independent investigator in hematological malignancy research, to discover effective therapeutics for blood cancers.